Evidence map›Paper›PMID 42426899›Full record

ArticlePilot and feasibility studies2026

Feasibility and tolerability of Musa sp. pseudo-stem core powder as a dietary supplement with gut microbiota-modulating potential: a pilot randomised controlled trial.

Hajara Aslam, Mojtaba Loftalani, Martin O'Hely, Michael Berk, Russell Keast, Simone Lewin, Shirani Gamlath, Heidi Staudacher, Felice N Jacka

Abstract read
In one paragraph

Article in Pilot and feasibility studies, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Hajara AslamThe Institute for Mental and Physical Health and Clinical Translation (IMPACT), Food & Mood Centre, School of Medicine and Barwon Health, Deakin University, Geelong, Victoria, Australia. f.hajara@deakin.edu.au.ORCID http://orcid.org/0000-0002-6023-1658
Mojtaba LoftalaniIMPACT, School of Medicine and Barwon Health, Deakin University, Geelong, Victoria, Australia.
Martin O'HelyIMPACT, School of Medicine and Barwon Health, Deakin University, Geelong, Victoria, Australia.
Michael BerkIMPACT, School of Medicine and Barwon Health, Deakin University, Geelong, Victoria, Australia.
Russell KeastCASS Food Research Centre, School of Exercise and Nutrition Sciences, Deakin University, Burwood, Victoria, Australia.
Simone LewinCASS Food Research Centre, School of Exercise and Nutrition Sciences, Deakin University, Burwood, Victoria, Australia.
Shirani GamlathCASS Food Research Centre, School of Exercise and Nutrition Sciences, Deakin University, Burwood, Victoria, Australia.
Heidi Staudacher *The Institute for Mental and Physical Health and Clinical Translation (IMPACT), Food & Mood Centre, School of Medicine and Barwon Health, Deakin University, Geelong, Victoria, Australia.
Felice N Jacka *The Institute for Mental and Physical Health and Clinical Translation (IMPACT), Food & Mood Centre, School of Medicine and Barwon Health, Deakin University, Geelong, Victoria, Australia.

Funding

Deakin University SEED funding
6 · The paper itself

Abstract

backgroundThe gut microbiota is increasingly recognised as a therapeutic target for mental disorders, with nutritional supplements providing a direct approach to modulating the gut microbiota. However, existing evidence largely focuses on single nutrients or phytochemicals, highlighting the need for novel multi-component interventions. This pilot study evaluated the feasibility and tolerability of a dietary supplement powder derived from Musa sp. pseudo-stem core that contains a combination of microbiota-modulating nutrients and phytochemicals.

methodsWe recruited 30 healthy adults, aged between 18 and 65 years, from the community to a triple-blinded, 4-week randomised placebo-controlled pilot trial. Participants were randomised to receive either 10 g/day of the Musa sp. pseudo-stem core powder or maltodextrin placebo. Supplement feasibility was defined as consuming at least 80% of the allocated supplement along with habitual diet. Tolerability was defined as no changes in gastrointestinal (GI) symptoms and stool consistency compared with placebo. Exploratory outcomes included psychological symptoms, quality of life, urinary hippurate measured using nuclear magnetic resonance spectroscopy, and stool gut microbiota profiling using 16S rRNA sequencing.

resultsAt the end of the study, 86% of the participants in the supplement group met the 80% consumption threshold, demonstrating intervention feasibility. There were no observed differences in the changes in GI symptoms or stool consistency between the supplement and placebo groups over the period of the study, indicating supplement tolerability. There were no observed differences in the changes in psychological symptoms, quality of life, and urine hippurate levels between groups at week 4. The weighted UniFrac distance showed a structural difference of the gut microbiota community between the supplement and placebo groups at week 4, although no observed differences were found in alpha diversity. Differences in the changes of two bacterial taxa each belonging to the family Anaerovoracaceae and Prevotellaceae were observed in the supplement group compared with the placebo group at week 4.

conclusionOur pilot study showed that Musa sp. pseudo-stem core powder was feasible and well-tolerated as a dietary supplement, with potential for modulating the gut microbiota. Future adequately powered trials are warranted to evaluate its effect on mental health and to elucidate underlying biological mechanisms.

trial registrationThe trial was registered with the Australian New Zealand Clinical Trials Registry (ACTRN12623000454673) on 2 May 2023.

Indexed as

Banana stem coreDietary supplementsFeasibilityFunctional nutrientsGut microbiotaMental health

Identifiers

PMID42426899
PMCPMC13656367

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.